Last 71,000 KRW
Change Today -1,800.00 / -2.47%
Volume 36.9K
069620 On Other Exchanges
Korea SE
As of 2:26 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

daewoong pharmaceutical co (069620) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/5/13 - 89,600
52 Week Low
06/26/13 - 53,300
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAEWOONG PHARMACEUTICAL CO (069620)

Related News

No related news articles were found.

daewoong pharmaceutical co (069620) Related Businessweek News

No Related Businessweek News Found

daewoong pharmaceutical co (069620) Details

Daewoong Pharmaceutical Co., Ltd. manufactures and sells prescription drugs in South Korea. The company offers various drugs for the treatment of neuropathic pain, non alcoholic fatty liver, Alzheimer's disease, chronic pain, fungal infection, gastric ulcer, lung cancer, pancreatic cancer, diabetic foot ulcer, acute wounds, oral mucositis, dressing combination, dental bonegraft, and spinal fusion. It also provides products to treat glabellar lines, type 1 and 2 diabetes, solid tumors, erectile dysfuction, leukemia, thrombosis, hyperlipidemia, hypertension, alzheimer's disease, antiemetic, antiulcer, anodynia, antitussive, mucolytic agents, contrast media, antidepressant, carbapenem antibiotics, asthma, hepatitis B, and carbapenem antibiotics. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Founded in 1945

daewoong pharmaceutical co (069620) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daewoong pharmaceutical co (069620) Key Developments

ALPHAEON Corporation Receives Exclusive License to Market Advanced Botulinum Toxin Type A Neurotoxin

Strathspey Crown Holdings LLC announced that it has acquired Evolus Inc. As part of the transaction ALPHAEON Corporation, has received the exclusive license to market, in both the U.S. and several international markets, an advanced Botulinum toxin Type A neurotoxin developed by Daewoong Pharmaceutical Co., Ltd. The Botulinum toxin Type A product will be marketed by ALPHAEON under the brand name EVOSYAL. The exclusive license also includes certain rights associated with future neurotoxin developments by Daewoong Pharmaceutical.

Medivir AB Discontinues Development of its Hepatitis B Compound MIV-210 with Daewoong Pharmaceutical Co. Ltd

Medivir AB announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical Co. Ltd. Under the terms of this collaboration agreement Daewoong has been responsible for the R&D work. MIV-210 has a demonstrably competitive antiviral activity but, like other drugs of this class, does not completely eradicate HBV. The commercial environment for HBV drugs, with the current standard of care approaching generic status, requires a robust cure profile. To achieve this cure profile would require combination with other drugs with different and new mechanisms.

Daewoong Pharmaceutical Co., Ltd. Presents at Fifth Annual ChinaBio(R) Partnering Forum 2013, May-29-2013

Daewoong Pharmaceutical Co., Ltd. Presents at Fifth Annual ChinaBio(R) Partnering Forum 2013, May-29-2013 . Venue: Shangri-La Hotel, 29 Zizhuyuan Road, Beijing 100089, China.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
069620:KS 71,000.00 KRW -1,800.00

069620 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 069620.
View Industry Companies

Industry Analysis


Industry Average

Valuation 069620 Industry Range
Price/Earnings 12.7x
Price/Sales 1.1x
Price/Book 1.7x
Price/Cash Flow 13.2x
TEV/Sales 1.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEWOONG PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at